| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 02/27/2003 | WO2003016351A2 N - cam related compounds modulating cell groth |
| 02/27/2003 | WO2003016341A2 Regulation of iron uptake |
| 02/27/2003 | WO2003016335A2 Irreversible cysteine protease inhibitors of legumain |
| 02/27/2003 | WO2003016314A1 1-alkyl 0r 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors |
| 02/27/2003 | WO2003016311A1 Tricyclic pyridin-2-one analogues as ligands for gaba-a receptors |
| 02/27/2003 | WO2003016291A1 ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR δ |
| 02/27/2003 | WO2003016270A2 Selective estrogen receptor modulators |
| 02/27/2003 | WO2003016269A1 5-amidino-n-(2-aminophenethyl)-n-hydroxybenzenesulfonamide derivative, medicinal composition containing the same, and intermediate therefor |
| 02/27/2003 | WO2003015820A1 GnRH AGONIST COMBINATION DRUGS |
| 02/27/2003 | WO2003015812A2 Beta-amyloid-analogue-t-cell epitop vaccine |
| 02/27/2003 | WO2003015805A1 Composition for removal of toxins |
| 02/27/2003 | WO2003015804A1 Treatment to improve central nervous system function |
| 02/27/2003 | WO2003015799A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate |
| 02/27/2003 | WO2003015797A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine |
| 02/27/2003 | WO2003015794A1 Methods and compositions for treating apoptosis associated disorders |
| 02/27/2003 | WO2003015791A1 Phophylactic and therapeutic use of hydroxysteroids |
| 02/27/2003 | WO2003015787A1 Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine |
| 02/27/2003 | WO2003015785A1 2h-phthalazin-1-ones and methods for use thereof |
| 02/27/2003 | WO2003015784A1 2-substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors |
| 02/27/2003 | WO2003015783A1 Method of treating alcoholism or alcohol abuse |
| 02/27/2003 | WO2003015780A2 Isoxazolopyridinones and use thereof in the treatment of parkinson's disease |
| 02/27/2003 | WO2003015776A1 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity |
| 02/27/2003 | WO2003015772A1 Inhibitors of polyq-aggregation |
| 02/27/2003 | WO2003015770A1 Novel combination |
| 02/27/2003 | WO2003015769A1 Aminoalkyl-substituted aromatic bicyclic compounds, method for the production thereof and their use as medicaments |
| 02/27/2003 | WO2003015768A2 Use of inhibitors of proline endopeptidase to modulate inositol (1,4,5) triphosphate concentration dependent on intracellular signal cascades |
| 02/27/2003 | WO2003015761A1 Selective estrogen receptor modulators |
| 02/27/2003 | WO2003015760A1 Use of dmso in the treatment of neurodegenerative diseases caused by prions |
| 02/27/2003 | WO2003015757A1 Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies |
| 02/27/2003 | WO2003015748A2 Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
| 02/27/2003 | WO2003015713A2 Treatment of glial tumors with glutamate antagonists |
| 02/27/2003 | WO2003015710A2 Combined drug and csf removal therapies and systems |
| 02/27/2003 | WO2003015699A2 Topical compositions and methods for treating pain |
| 02/27/2003 | WO2003015693A2 Screening and therapeutic methods for promoting wakefulness and sleep |
| 02/27/2003 | WO2003015691A2 RAPID IMPROVEMENT OF COGNITION IN CONDITIONS RELATED TO A$g(b) |
| 02/27/2003 | WO2003015690A2 Method for treating primary insomnia |
| 02/27/2003 | WO2003015612A2 Materials and methods to promote repair of nerve tissue |
| 02/27/2003 | WO2003015516A1 Compositions and methods for treatment of mitochondrial diseases |
| 02/27/2003 | WO2003015494A2 Tocopherol enriched compositions and amelioration of inflammatory symptoms |
| 02/27/2003 | WO2003002123A3 Therapeutic combinations for the treatment of hormone deficiencies |
| 02/27/2003 | WO2003001881A3 Cell-based high-throughput screening methods |
| 02/27/2003 | WO2003000181A3 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 02/27/2003 | WO2002100862A3 Novel substituted tetracyclic imidazole derivatives, processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine |
| 02/27/2003 | WO2002098865A3 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof |
| 02/27/2003 | WO2002097046A3 B7 related protein-2 molecules and uses thereof |
| 02/27/2003 | WO2002096881A8 Method for preparation of 10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide and 10,11-dihydro-10-0x0-5h-dibenz/b,f/azepine-5-carboxamide |
| 02/27/2003 | WO2002092602A3 PROCESSES FOR THE SYNTHESIS OF DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO-[2,3-f] QUINOLINE |
| 02/27/2003 | WO2002092588A3 Aromatic sulfone hydroxamates and their use as protease inhibitors |
| 02/27/2003 | WO2002089749A3 Arylsulfonamide ethers, and methods of use thereof |
| 02/27/2003 | WO2002089740A3 Sulfonamides |
| 02/27/2003 | WO2002088141A3 ANTIPSYCHOTIC AMINOMETHYL DERIVATIVES OF 7,8-DIHYDRO-2,6,9-TRIOXA-3-AZA-CYCLOPENTA[a]NAPHTHALENE |
| 02/27/2003 | WO2002087553A3 Use of desoxypeganine for treating central nervous system symptoms resulting from intoxications by psychotrops |
| 02/27/2003 | WO2002087423A3 Carbonic anhydrase activators for enhancing learning and memory |
| 02/27/2003 | WO2002085903A3 Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
| 02/27/2003 | WO2002083135A3 Use of buprenorphine for the manufacture of a transdermal delivery device for the treatment of urinary incontinence, especially urge incontinence |
| 02/27/2003 | WO2002072542A3 Ph-dependent nmda receptor antagonists |
| 02/27/2003 | WO2002066420A3 Tryptase inhibitors |
| 02/27/2003 | WO2002064590A3 Carboline derivatives |
| 02/27/2003 | WO2002060411A3 Process for production of nanoparticles and microparticles by spray freezing into liquid |
| 02/27/2003 | WO2002060388A3 Acyl sulfamides for treatment of obesity, diabetes and lipid disorders |
| 02/27/2003 | WO2002055093A3 Activated charcoal based composition and method for reducing hangover symptoms associated with the consumption of alcohol containing beverages |
| 02/27/2003 | WO2002046193A3 Heterocyclic ether substituted imidazoquinolines |
| 02/27/2003 | WO2002028865A3 Condensed pyridoindole derivatives |
| 02/27/2003 | WO2002022212A3 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 02/27/2003 | WO2002022111A3 Combination of lipoic acids and conjugated acids for treating diabetic disorders |
| 02/27/2003 | WO2002020767A3 G-csf analog compositions and methods |
| 02/27/2003 | WO2002017919A3 Use of threo-methylphenidate compounds to enhance memory |
| 02/27/2003 | WO2002008407A9 Gene-targeted non-human mammal with human fad presenilin mutation and generational offspring |
| 02/27/2003 | WO2002002797A3 Regulation of human 11 beta-hydroxysteroid dehydrogenase 1-like enzyme |
| 02/27/2003 | WO2002000691A3 Polynucleotides and polypeptides encoded thereby |
| 02/27/2003 | WO2001098471A3 Human phosphodiesterases |
| 02/27/2003 | WO2001098267A8 3-azabicyclo (3.1.0) hexane derivatives having opioid receptor affinity |
| 02/27/2003 | WO2001092892A3 Methods to identify compounds that modulate rage |
| 02/27/2003 | WO2001085924A3 MODULATION OF η-SECRETASE ACTIVITY |
| 02/27/2003 | US20030041340 Animal model for fatty acid amide-related neurobehaviors |
| 02/27/2003 | US20030040631 As chemical intermediates used for the preparation of S-alpha-ethyl-2-oxo-1-pyrrolidine acetamide |
| 02/27/2003 | US20030040625 For therapy of hypertension, type 2 insulin-resistant diabetes mellitus, ecalmpsia and preeclampsia |
| 02/27/2003 | US20030040607 Hematopoietic cell E-selection/L-selectin ligand polypeptides and methods of use thereof |
| 02/27/2003 | US20030040541 Administering bismuth subgallate to inhibit the production of nitric oxide synthases (NOS) |
| 02/27/2003 | US20030040537 Treatment of migraine headache |
| 02/27/2003 | US20030040536 For therapy of disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease |
| 02/27/2003 | US20030040535 Tetrazole compounds as thyroid receptor ligands |
| 02/27/2003 | US20030040533 For use as hypoglycaemic and hypolipidaemic agents |
| 02/27/2003 | US20030040532 Methods for treating dementia due to HIV disease |
| 02/27/2003 | US20030040530 Phenoxypropanolamines, method for producing them and pharmaceutical compositions containning them |
| 02/27/2003 | US20030040523 Pyrimidine compounds and their use as modulators of chemokine receptor activity |
| 02/27/2003 | US20030040522 Process for the production of N-[3-(3-cyanopyrazolo[1,5-a] pyrimidin-7-yl) phenyl]-N-ethylacetamide (zaleplon) |
| 02/27/2003 | US20030040518 For therapy of neurodegenerative diseases and for the regeneration or prevention of degeneration of lesioned and damaged neurons degeneration of lesioned and damaged neurons |
| 02/27/2003 | US20030040517 For use in therapy of pain, fever, inflammation of a variety of conditions and diseases |
| 02/27/2003 | US20030040513 P2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases |
| 02/27/2003 | US20030040510 Selective estrogen receptor modulators in combination with estrogens |
| 02/27/2003 | US20030040509 Methods and compositions for treating diseases associated with excesses in ACE |
| 02/27/2003 | US20030040508 Altering the conformational equilibrium of the A- ring of a 1 alpha -hydroxylated vitamin D compound to favor a chair conformation for A-ring that presents the 1 alpha-hydroxyl in an axial orientation |
| 02/27/2003 | US20030040500 Replication incompetent herpes virus vectors |
| 02/27/2003 | US20030040486 Alternating intrathecal administration to the mammal of a pharmaceutically effective dose of opioid receptor agonist for first period of time, and dose of at least one opioid receptor-like receptor 1 agonist for a second period of time |
| 02/27/2003 | US20030040465 Neuregulins as modulators of cellular communication |
| 02/27/2003 | US20030040464 Method of treating or preventing attention defecit hyperactivity disorder |
| 02/27/2003 | US20030040112 Materials and methods for nerve grafting, selection of nerve grafts, and in vitro nerve tissue culture |
| 02/27/2003 | US20030040083 Dual specificity antibodies and methods of making and using |
| 02/27/2003 | US20030040046 Netrin receptors |